A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors
Baselga, J., De Jonge, M. J., Rodon, J., Burris, H. A., Birle, D. C., De Buck, S. S., Demanse, D., Ru, Q. C., Goldbrunner, M., Bendell, J. C.
Published in Journal of clinical oncology (20.05.2010)
Published in Journal of clinical oncology (20.05.2010)
Get full text
Journal Article